176 related articles for article (PubMed ID: 9221567)
1. [A new purine analog in the treatment of hematologic malignancy. I. Fludarabine].
Vásová I; Penka M; Hájek R; Mayer J; Krahulcová E
Vnitr Lek; 1997 Jan; 43(1):45-50. PubMed ID: 9221567
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with fludarabine in hemato-oncology.
Keating MJ; O'Brien S; McLaughlin P; Dimopoulos M; Gandhi V; Plunkett W; Lerner S; Kantarjian H; Estey E
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S83-91. PubMed ID: 9137961
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine in Waldenstrom's macroglobulinemia.
Leblond V; Choquet S
Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.
Ross SR; McTavish D; Faulds D
Drugs; 1993 May; 45(5):737-59. PubMed ID: 7686467
[TBL] [Abstract][Full Text] [Related]
5. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
Varga F; Lehoczky D; Demeter J
Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
[TBL] [Abstract][Full Text] [Related]
6. The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
Lenz G; Hiddemann W; Dreyling M
Cancer; 2004 Sep; 101(5):883-93. PubMed ID: 15329894
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine in lymphoproliferative malignancies: a single-centre experience.
Prabhash K; Vikram GS; Nair R; Sengar M; Gujral S; Bakshi A; Gupta S; Parikh PM
Natl Med J India; 2008; 21(4):171-4. PubMed ID: 19267037
[TBL] [Abstract][Full Text] [Related]
8. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Carney DA; Westerman DA; Tam CS; Milner A; Prince HM; Kenealy M; Wolf M; Januszewicz EH; Ritchie D; Came N; Seymour JF
Leukemia; 2010 Dec; 24(12):2056-62. PubMed ID: 20962860
[TBL] [Abstract][Full Text] [Related]
10. The expanding role of fludarabine in hematologic malignancies.
Keating MJ; O'Brien S; Robertson LE; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Li YY; Gandhi V
Leuk Lymphoma; 1994; 14 Suppl 2():11-6. PubMed ID: 7533576
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with fludarabine in leukaemia.
Keating MJ; Estey E; O'Brien S; Kantarjian H; Robertson LE; Plunkett W
Drugs; 1994; 47 Suppl 6():39-49. PubMed ID: 7525188
[TBL] [Abstract][Full Text] [Related]
12. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
Martell RE; Peterson BL; Cohen HJ; Petros WP; Rai KR; Morrison VA; Elias L; Shepherd L; Hines J; Larson RA; Schiffer CA; Hurwitz HI
Cancer Chemother Pharmacol; 2002 Jul; 50(1):37-45. PubMed ID: 12111110
[TBL] [Abstract][Full Text] [Related]
13. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
14. New prospects in the treatment of indolent lymphomas with purine analogues.
Cheson BD
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S27-36. PubMed ID: 9672772
[TBL] [Abstract][Full Text] [Related]
15. New initiatives with fludarabine monophosphate in hematologic malignancies.
Keating MJ; O'Brien S; Robertson LE; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Yang LY; Gandhi V
Semin Oncol; 1993 Oct; 20(5 Suppl 7):13-20. PubMed ID: 7694371
[TBL] [Abstract][Full Text] [Related]
16. Role of fludarabine in hematological malignancies.
Montillo M; Ricci F; Tedeschi A
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1141-61. PubMed ID: 17020450
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
[TBL] [Abstract][Full Text] [Related]
19. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Perkins JG; Flynn JM; Howard RS; Byrd JC
Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
[TBL] [Abstract][Full Text] [Related]
20. Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders.
Fidias P; Chabner BA; Grossbard ML
Oncologist; 1996; 1(3):125-139. PubMed ID: 10387979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]